



NBS (NYSE Alternext US) **\$1.98**

MARKET DATA

52-Week High/Low	\$2.20/\$0.41
Ave. Daily Volume	27,000 sh
Shares Outstanding, Fully Diluted (approx)*	7.95 mil sh
Public Float (approx)	5.6 mil sh
Short Position/Ratio	NMF

*Due to recent \$11 mil PIPE in April, diluted share count will increase substantially.

FINANCIAL DATA

Market Capitalization (Fully Diluted)	\$15.74 mil
Cash & Equivalents (3/31)*	\$392,791
Book Value (approx 3/31)	N/A
Short-term Debt (approx 3/31)**#	\$1.23 mil
Long-term Debt (approx 3/31)	\$0
Total Debt (approx 3/31)**#	\$1.23 mil
Total Debt/Equity (approx)	N/A
Total Debt/Total Capitalization (approx)	N/A

*Not including \$11 mil received (PIPE) in April 2009.

**Not including \$1.15 mil repaid in April.

#Exclusive of other liabilities of approx. \$1.4 mil.

	Revs	EPS	Oper Cash Flow
2007	\$ 231,664	\$ (3.18)	\$ (6,132,424)
Q1	\$ 693	\$ (0.52)	\$ (1,401,739)
Q2	\$ 23,528	\$ (0.43)	\$ (1,296,397)
Q3	\$ 25,248	\$ (0.30)	\$ (920,114)
Q4	\$ 34,072	\$ (0.31)	\$ (1,113,915)
2008	\$ 83,541	\$ (1.53)	\$ (4,732,165)
Q1	\$ 45,138	\$ (0.24)	\$ (1,252,999)
2009			

EPS numbers might not add exactly due to rounding.

CONTACT INFORMATION:

Phone Number
(212) 584-4180

Address
420 Lexington Ave., Suite 450,
New York, NY 10170

Website

www.neostem.com

Email

rsmith@neostem.com

NeoStem, Inc. is a
Pro-Active Capital Group Client
646-315-7070

www.pro-activecapital.com



NeoStem, Inc.

SUMMER 2009

COMPANY PROFILE

NeoStem, Inc. provides adult stem processing, collection and banking services and is developing a network of adult stem cell collection centers that enable people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The co. is involved in R&D through their license to identify and isolate VSELs (very small embryonic-like stem cells) and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration.

- NeoStem is one of only a very small number of providers of autologous adult stem cell collection facilities in operation globally.
- Stem cell transplants (SCTs) (or bone marrow transplants, BMTs) are currently used as standard, medically accepted treatments for approx. 70 blood cancers, diseases and illnesses, as well as for some solid tumors. There are a large number of SCT trials for additional uses ongoing.
- The co. currently has approx. 6 stem cell collection facilities in operation and 2 more to be operational shortly.
- The co. is pursuing additional initiatives including their VSEL R&D as well as anti-aging and regenerative medicine therapies and technologies.
- The field of regenerative medicine is gaining interest. Pfizer recently launched Pfizer Regenerative Medicine and will be spending \$100 mil over the next 5 years to develop therapies from stem cells.
- The co. is pursuing joint ventures, alliances, partnerships and acquisitions, as well as obtaining licenses and patents. The co. is pursuing a myriad of opportunities in China.
- The co. will be receiving \$800,000 in funding from the Dept of Defense (DOD) for evaluating the potential use of adult stem cell therapy for the treatment of injuries.

